High-performance liquid chromatographic determination of glipizide in human plasma and urine.
A sensitive and selective high-performance liquid chromatographic method for determination of intact glipizide in human plasma or urine has been developed. The plasma and urine samples were acid-buffered, before tolbutamide was added as internal standard. The samples were extracted with benzene, and the organic layer was evaporated to dryness. The residue was dissolved in equilibrated mobile phase (acetonitrile-0.01 M phosphate buffer pH 3.5, 35:65), and an aliquot of 20 microliters was chromatographed on a Spherisorb ODS reversed-phase column. Quantitation was achieved by monitoring the ultraviolet absorbance at 275 nm. The response was linear (0-1000 ng/ml) and the detection limit was 5-10 ng/ml in plasma or urine. The within-assay variation was less than or equal to 10%. No interferences from metabolites or endogenous constituents were observed. The utility of the assay was demonstrated by determining glipizide in samples from a diabetic subject receiving a therapeutic dose of 5 mg of the drug.
Department of Pharmacy, Karolinska Institute, Huddinge Hospital, Sweden.
H
H
Emilsson
D002851:Chromatography, High Pressure Liquid; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism; D005913:Glipizide / Q000032:analysis* / Q000097:blood / Q000652:urine; D006801:Humans; D007202:Indicators and Reagents; D013453:Sulfonylurea Compounds / Q000032:analysis*
D007202:Indicators and Reagents; D013453:Sulfonylurea Compounds; D005913:Glipizide